Trial Outcomes & Findings for Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) (NCT NCT01540370)

NCT ID: NCT01540370

Last Updated: 2013-09-19

Results Overview

Intra-rater agreement (for each of the 6 raters) of Large Step angle width (range: 0.5 to 5.5 with 0.5 unit intervals) was evaluated using weighted kappa (Fleiss-Cohen) statistics. The angle is the area between the iris and cornea of the eye. Each examiner performed a pair of angle-width measurements by goniometric lens predilation (ie, 2 measurements per examiner). The degree of agreement within raters was interpreted according to Landis and Koch, where: \<0:poor, 0.00-0.20:slight, 0.21-0.40:fair, 0.41-0.60:moderate, 0.61-0.80:substantial, and 0.81-1.00:almost perfect.

Recruitment status

COMPLETED

Target enrollment

102 participants

Primary outcome timeframe

Day 1

Results posted on

2013-09-19

Participant Flow

Participant milestones

Participant milestones
Measure
Patients With OAG and/or OHT
Patients with OAG and/or OHT.
Overall Study
STARTED
102
Overall Study
COMPLETED
100
Overall Study
NOT COMPLETED
2

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patients With OAG and/or OHT
n=102 Participants
Patients with OAG and/or OHT.
Age Continuous
64.1 Years
STANDARD_DEVIATION 12.18 • n=5 Participants
Sex: Female, Male
Female
53 Participants
n=5 Participants
Sex: Female, Male
Male
49 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Day 1

Population: Modified Intent to Treat: enrolled patients with unobstructed and measurable inferior angles by goniometric reading and anterior segment optical coherence tomography (OCT)

Intra-rater agreement (for each of the 6 raters) of Large Step angle width (range: 0.5 to 5.5 with 0.5 unit intervals) was evaluated using weighted kappa (Fleiss-Cohen) statistics. The angle is the area between the iris and cornea of the eye. Each examiner performed a pair of angle-width measurements by goniometric lens predilation (ie, 2 measurements per examiner). The degree of agreement within raters was interpreted according to Landis and Koch, where: \<0:poor, 0.00-0.20:slight, 0.21-0.40:fair, 0.41-0.60:moderate, 0.61-0.80:substantial, and 0.81-1.00:almost perfect.

Outcome measures

Outcome measures
Measure
Patients With OAG and/or OHT
n=100 Participants
Patients with OAG and/or OHT.
Intra- Examiner Agreement in Angle Width by Goniometric Lens
0.88 Kappa statistics

PRIMARY outcome

Timeframe: Day 1

Population: Modified Intent to Treat: enrolled patients with unobstructed and measurable inferior angles by goniometric reading and anterior segment optical coherence tomography (OCT)

Inter-rater agreement (among 6 raters) of Large Step angle width (range: 0.5 to 5.5 with 0.5 unit intervals) was evaluated using weighted kappa (Fleiss-Cohen) statistics. The angle is the area between the iris and cornea of the eye. Each examiner performed a pair of angle-width measurements by goniometric lens predilation (ie, 2 measurements per examiner). The degree of agreement within raters was interpreted according to Landis and Koch, where: \<0:poor, 0.00-0.20:slight, 0.21-0.40:fair, 0.41-0.60:moderate, 0.61-0.80:substantial, and 0.81-1.00:almost perfect.

Outcome measures

Outcome measures
Measure
Patients With OAG and/or OHT
n=100 Participants
Patients with OAG and/or OHT.
Inter- Examiner Agreement in Angle Width by Goniometric Lens
0.72 Kappa statistics
Interval 0.51 to 0.85

Adverse Events

Patients With OAG and/or OHT

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Therapeutic Area Head,

Allergan, Inc

Phone: 714-246-4500

Results disclosure agreements

  • Principal investigator is a sponsor employee A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
  • Publication restrictions are in place

Restriction type: OTHER